Circulating tumor cells in multiple myeloma serve as a compound biomarker for bone marrow high-risk genomic alterations and tumor load, according to a 2026 study published in Blood by Fokkema and colleagues. This blood-based marker helps clinicians evaluate aggressive disease features without always relying solely on repeated bone marrow biopsies.
Genomic Complexity and Circulating Tumor Cells
Elevated circulating tumor cells reflect high proliferation and genomic complexity in multiple myeloma, as detailed in research led by Garces and colleagues in Hemasphere. Monitoring these cells offers a minimally invasive window into the genetic landscape of the cancer.
Did you know? Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load.
Refining Risk Stratification with Staging Systems
Traditional staging has evolved significantly from the original International Staging System introduced by Greipp and colleagues in 2005. Subsequent updates include the Revised International Staging System for multiple myeloma by Palumbo and colleagues in 2015, and the second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma published by D’Agostino and colleagues in 2022. Furthermore, the International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma released in 2025 established new definitions for high-risk multiple myeloma, which Maclachlan and colleagues demonstrated successfully predict outcomes with daratumumab-based quadruplet regimens for NDMM.
Minimally Invasive Disease Monitoring
Frequently Asked Questions
- What are circulating tumor cells in multiple myeloma? They are malignant plasma cells that have escaped the bone marrow and entered the peripheral bloodstream, signaling higher disease aggression.
- How do doctors measure these cells? Clinicians use advanced methods like next-generation flow cytometry and immunomagnetic enrichment on blood samples.
- Why is risk stratification important? It helps medical teams predict patient outcomes and tailor therapies, such as daratumumab-based quadruplet regimens, to high-risk profiles.
Want to stay updated on the latest hematology research and diagnostic breakthroughs? Subscribe to our newsletter or explore our archive for more expert insights on cancer care.
Worth a look